Oculis Completes Series A Financing

REYKJAVIK, Iceland--(BUSINESS WIRE)--Oculis announced today the close of a Series A financing round, led by Brunnur Ventures and Silfurberg. The new capital will support continued development of the company's patented solubilizing nanoparticle (SNP) drug delivery platform and the company’s drug candidates, including the first topical eye-drops for treatment of diabetic macular edema. SNP Drug Delivery Platform – breakthrough in eye-drop technology Oculis' SNP platform technology is specifically